Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab first-in-human phase 1/2 study in relapsed or refractory multiple myeloma
NL-OMON56207Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2019
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of teclistamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Recommended Phase 2 dose and schedule, Safety and tolerability at RP2D and 2 more. Started Jan 2019; status: recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56207.